Global Generic Drugs Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030

Global Generic Drugs Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030


Summary

A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.

According to APO Research, The global Generic Drugs market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

North American market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global companies of Generic Drugs include Teva, Novartis - Sandoz, Mylan, Sun Pharmaceutical, Aspen, Fresenius Kabi, Pfizer (Hospira), Sanofi and Aurobindo, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Generic Drugs, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Generic Drugs, also provides the value of main regions and countries. Of the upcoming market potential for Generic Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Generic Drugs revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Generic Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Generic Drugs company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.

Generic Drugs segment by Company

Teva
Novartis - Sandoz
Mylan
Sun Pharmaceutical
Aspen
Fresenius Kabi
Pfizer (Hospira)
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO (Par Pharmaceutical)
Stada Arzneimittel
Krka Group
Nichi-Iko Pharmaceutical
Valeant
Zydus Cadila
Hikma
Pharmaniaga Berhad
Hovid Berhad
Duopharma Biotech
Kotra Pharma
HOE Pharmaceutical
Y.S.P. Industries
Generic Drugs segment by Type

Prescription
Non-Prescription Drugs
Generic Drugs segment by Application

Hospital
Clinic
Others
Generic Drugs segment by Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Generic Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Generic Drugs key companies, revenue, market share, and recent developments.
3. To split the Generic Drugs breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Generic Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Generic Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze Generic Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Generic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Generic Drugs industry.
Chapter 3: Detailed analysis of Generic Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Generic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Generic Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.


1 Market Overview
1.1 Product Definition
1.2 Global Generic Drugs Market Size, 2019 VS 2023 VS 2030
1.3 Global Generic Drugs Market Size (2019-2030)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Generic Drugs Market Dynamics
2.1 Generic Drugs Industry Trends
2.2 Generic Drugs Industry Drivers
2.3 Generic Drugs Industry Opportunities and Challenges
2.4 Generic Drugs Industry Restraints
3 Generic Drugs Market by Company
3.1 Global Generic Drugs Company Revenue Ranking in 2023
3.2 Global Generic Drugs Revenue by Company (2019-2024)
3.3 Global Generic Drugs Company Ranking, 2022 VS 2023 VS 2024
3.4 Global Generic Drugs Company Manufacturing Base & Headquarters
3.5 Global Generic Drugs Company, Product Type & Application
3.6 Global Generic Drugs Company Commercialization Time
3.7 Market Competitive Analysis
3.7.1 Global Generic Drugs Market CR5 and HHI
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.7.3 2023 Generic Drugs Tier 1, Tier 2, and Tier
3.8 Mergers & Acquisitions, Expansion
4 Generic Drugs Market by Type
4.1 Generic Drugs Type Introduction
4.1.1 Prescription
4.1.2 Non-Prescription Drugs
4.2 Global Generic Drugs Sales Value by Type
4.2.1 Global Generic Drugs Sales Value by Type (2019 VS 2023 VS 2030)
4.2.2 Global Generic Drugs Sales Value by Type (2019-2030)
4.2.3 Global Generic Drugs Sales Value Share by Type (2019-2030)
5 Generic Drugs Market by Application
5.1 Generic Drugs Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.1.3 Others
5.2 Global Generic Drugs Sales Value by Application
5.2.1 Global Generic Drugs Sales Value by Application (2019 VS 2023 VS 2030)
5.2.2 Global Generic Drugs Sales Value by Application (2019-2030)
5.2.3 Global Generic Drugs Sales Value Share by Application (2019-2030)
6 Generic Drugs Market by Region
6.1 Global Generic Drugs Sales Value by Region: 2019 VS 2023 VS 2030
6.2 Global Generic Drugs Sales Value by Region (2019-2030)
6.2.1 Global Generic Drugs Sales Value by Region: 2019-2024
6.2.2 Global Generic Drugs Sales Value by Region (2025-2030)
6.3 North America
6.3.1 North America Generic Drugs Sales Value (2019-2030)
6.3.2 North America Generic Drugs Sales Value Share by Country, 2023 VS 2030
6.4 Europe
6.4.1 Europe Generic Drugs Sales Value (2019-2030)
6.4.2 Europe Generic Drugs Sales Value Share by Country, 2023 VS 2030
6.5 Asia-Pacific
6.5.1 Asia-Pacific Generic Drugs Sales Value (2019-2030)
6.5.2 Asia-Pacific Generic Drugs Sales Value Share by Country, 2023 VS 2030
6.6 Latin America
6.6.1 Latin America Generic Drugs Sales Value (2019-2030)
6.6.2 Latin America Generic Drugs Sales Value Share by Country, 2023 VS 2030
6.7 Middle East & Africa
6.7.1 Middle East & Africa Generic Drugs Sales Value (2019-2030)
6.7.2 Middle East & Africa Generic Drugs Sales Value Share by Country, 2023 VS 2030
7 Generic Drugs Market by Country
7.1 Global Generic Drugs Sales Value by Country: 2019 VS 2023 VS 2030
7.2 Global Generic Drugs Sales Value by Country (2019-2030)
7.2.1 Global Generic Drugs Sales Value by Country (2019-2024)
7.2.2 Global Generic Drugs Sales Value by Country (2025-2030)
7.3 USA
7.3.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.3.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.3.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.4 Canada
7.4.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.4.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.4.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.5 Germany
7.5.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.5.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.6 France
7.6.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.6.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.7 U.K.
7.7.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.7.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.8 Italy
7.8.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.8.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.9 Netherlands
7.9.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.9.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.10 Nordic Countries
7.10.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.10.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.11 China
7.11.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.11.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.12 Japan
7.12.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.12.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.13 South Korea
7.13.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.13.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.14 Southeast Asia
7.14.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.14.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.15 India
7.15.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.15.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.16 Australia
7.16.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.16.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.17 Mexico
7.17.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.17.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.18 Brazil
7.18.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.18.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.19 Turkey
7.19.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.19.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.20 Saudi Arabia
7.20.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.20.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.21 UAE
7.21.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.21.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
8 Company Profiles
8.1 Teva
8.1.1 Teva Comapny Information
8.1.2 Teva Business Overview
8.1.3 Teva Generic Drugs Revenue and Gross Margin (2019-2024)
8.1.4 Teva Generic Drugs Product Portfolio
8.1.5 Teva Recent Developments
8.2 Novartis - Sandoz
8.2.1 Novartis - Sandoz Comapny Information
8.2.2 Novartis - Sandoz Business Overview
8.2.3 Novartis - Sandoz Generic Drugs Revenue and Gross Margin (2019-2024)
8.2.4 Novartis - Sandoz Generic Drugs Product Portfolio
8.2.5 Novartis - Sandoz Recent Developments
8.3 Mylan
8.3.1 Mylan Comapny Information
8.3.2 Mylan Business Overview
8.3.3 Mylan Generic Drugs Revenue and Gross Margin (2019-2024)
8.3.4 Mylan Generic Drugs Product Portfolio
8.3.5 Mylan Recent Developments
8.4 Sun Pharmaceutical
8.4.1 Sun Pharmaceutical Comapny Information
8.4.2 Sun Pharmaceutical Business Overview
8.4.3 Sun Pharmaceutical Generic Drugs Revenue and Gross Margin (2019-2024)
8.4.4 Sun Pharmaceutical Generic Drugs Product Portfolio
8.4.5 Sun Pharmaceutical Recent Developments
8.5 Aspen
8.5.1 Aspen Comapny Information
8.5.2 Aspen Business Overview
8.5.3 Aspen Generic Drugs Revenue and Gross Margin (2019-2024)
8.5.4 Aspen Generic Drugs Product Portfolio
8.5.5 Aspen Recent Developments
8.6 Fresenius Kabi
8.6.1 Fresenius Kabi Comapny Information
8.6.2 Fresenius Kabi Business Overview
8.6.3 Fresenius Kabi Generic Drugs Revenue and Gross Margin (2019-2024)
8.6.4 Fresenius Kabi Generic Drugs Product Portfolio
8.6.5 Fresenius Kabi Recent Developments
8.7 Pfizer (Hospira)
8.7.1 Pfizer (Hospira) Comapny Information
8.7.2 Pfizer (Hospira) Business Overview
8.7.3 Pfizer (Hospira) Generic Drugs Revenue and Gross Margin (2019-2024)
8.7.4 Pfizer (Hospira) Generic Drugs Product Portfolio
8.7.5 Pfizer (Hospira) Recent Developments
8.8 Sanofi
8.8.1 Sanofi Comapny Information
8.8.2 Sanofi Business Overview
8.8.3 Sanofi Generic Drugs Revenue and Gross Margin (2019-2024)
8.8.4 Sanofi Generic Drugs Product Portfolio
8.8.5 Sanofi Recent Developments
8.9 Aurobindo
8.9.1 Aurobindo Comapny Information
8.9.2 Aurobindo Business Overview
8.9.3 Aurobindo Generic Drugs Revenue and Gross Margin (2019-2024)
8.9.4 Aurobindo Generic Drugs Product Portfolio
8.9.5 Aurobindo Recent Developments
8.10 Lupin
8.10.1 Lupin Comapny Information
8.10.2 Lupin Business Overview
8.10.3 Lupin Generic Drugs Revenue and Gross Margin (2019-2024)
8.10.4 Lupin Generic Drugs Product Portfolio
8.10.5 Lupin Recent Developments
8.11 Dr. Reddy's
8.11.1 Dr. Reddy's Comapny Information
8.11.2 Dr. Reddy's Business Overview
8.11.3 Dr. Reddy's Generic Drugs Revenue and Gross Margin (2019-2024)
8.11.4 Dr. Reddy's Generic Drugs Product Portfolio
8.11.5 Dr. Reddy's Recent Developments
8.12 Apotex
8.12.1 Apotex Comapny Information
8.12.2 Apotex Business Overview
8.12.3 Apotex Generic Drugs Revenue and Gross Margin (2019-2024)
8.12.4 Apotex Generic Drugs Product Portfolio
8.12.5 Apotex Recent Developments
8.13 Cipla
8.13.1 Cipla Comapny Information
8.13.2 Cipla Business Overview
8.13.3 Cipla Generic Drugs Revenue and Gross Margin (2019-2024)
8.13.4 Cipla Generic Drugs Product Portfolio
8.13.5 Cipla Recent Developments
8.14 ENDO (Par Pharmaceutical)
8.14.1 ENDO (Par Pharmaceutical) Comapny Information
8.14.2 ENDO (Par Pharmaceutical) Business Overview
8.14.3 ENDO (Par Pharmaceutical) Generic Drugs Revenue and Gross Margin (2019-2024)
8.14.4 ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio
8.14.5 ENDO (Par Pharmaceutical) Recent Developments
8.15 Stada Arzneimittel
8.15.1 Stada Arzneimittel Comapny Information
8.15.2 Stada Arzneimittel Business Overview
8.15.3 Stada Arzneimittel Generic Drugs Revenue and Gross Margin (2019-2024)
8.15.4 Stada Arzneimittel Generic Drugs Product Portfolio
8.15.5 Stada Arzneimittel Recent Developments
8.16 Krka Group
8.16.1 Krka Group Comapny Information
8.16.2 Krka Group Business Overview
8.16.3 Krka Group Generic Drugs Revenue and Gross Margin (2019-2024)
8.16.4 Krka Group Generic Drugs Product Portfolio
8.16.5 Krka Group Recent Developments
8.17 Nichi-Iko Pharmaceutical
8.17.1 Nichi-Iko Pharmaceutical Comapny Information
8.17.2 Nichi-Iko Pharmaceutical Business Overview
8.17.3 Nichi-Iko Pharmaceutical Generic Drugs Revenue and Gross Margin (2019-2024)
8.17.4 Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio
8.17.5 Nichi-Iko Pharmaceutical Recent Developments
8.18 Valeant
8.18.1 Valeant Comapny Information
8.18.2 Valeant Business Overview
8.18.3 Valeant Generic Drugs Revenue and Gross Margin (2019-2024)
8.18.4 Valeant Generic Drugs Product Portfolio
8.18.5 Valeant Recent Developments
8.19 Zydus Cadila
8.19.1 Zydus Cadila Comapny Information
8.19.2 Zydus Cadila Business Overview
8.19.3 Zydus Cadila Generic Drugs Revenue and Gross Margin (2019-2024)
8.19.4 Zydus Cadila Generic Drugs Product Portfolio
8.19.5 Zydus Cadila Recent Developments
8.20 Hikma
8.20.1 Hikma Comapny Information
8.20.2 Hikma Business Overview
8.20.3 Hikma Generic Drugs Revenue and Gross Margin (2019-2024)
8.20.4 Hikma Generic Drugs Product Portfolio
8.20.5 Hikma Recent Developments
8.21 Pharmaniaga Berhad
8.21.1 Pharmaniaga Berhad Comapny Information
8.21.2 Pharmaniaga Berhad Business Overview
8.21.3 Pharmaniaga Berhad Generic Drugs Revenue and Gross Margin (2019-2024)
8.21.4 Pharmaniaga Berhad Generic Drugs Product Portfolio
8.21.5 Pharmaniaga Berhad Recent Developments
8.22 Hovid Berhad
8.22.1 Hovid Berhad Comapny Information
8.22.2 Hovid Berhad Business Overview
8.22.3 Hovid Berhad Generic Drugs Revenue and Gross Margin (2019-2024)
8.22.4 Hovid Berhad Generic Drugs Product Portfolio
8.22.5 Hovid Berhad Recent Developments
8.23 Duopharma Biotech
8.23.1 Duopharma Biotech Comapny Information
8.23.2 Duopharma Biotech Business Overview
8.23.3 Duopharma Biotech Generic Drugs Revenue and Gross Margin (2019-2024)
8.23.4 Duopharma Biotech Generic Drugs Product Portfolio
8.23.5 Duopharma Biotech Recent Developments
8.24 Kotra Pharma
8.24.1 Kotra Pharma Comapny Information
8.24.2 Kotra Pharma Business Overview
8.24.3 Kotra Pharma Generic Drugs Revenue and Gross Margin (2019-2024)
8.24.4 Kotra Pharma Generic Drugs Product Portfolio
8.24.5 Kotra Pharma Recent Developments
8.25 HOE Pharmaceutical
8.25.1 HOE Pharmaceutical Comapny Information
8.25.2 HOE Pharmaceutical Business Overview
8.25.3 HOE Pharmaceutical Generic Drugs Revenue and Gross Margin (2019-2024)
8.25.4 HOE Pharmaceutical Generic Drugs Product Portfolio
8.25.5 HOE Pharmaceutical Recent Developments
8.26 Y.S.P. Industries
8.26.1 Y.S.P. Industries Comapny Information
8.26.2 Y.S.P. Industries Business Overview
8.26.3 Y.S.P. Industries Generic Drugs Revenue and Gross Margin (2019-2024)
8.26.4 Y.S.P. Industries Generic Drugs Product Portfolio
8.26.5 Y.S.P. Industries Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings